We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Evgen Pharma Plc | LSE:EVG | London | Ordinary Share | GB00BSVYN304 | ORD 0.25P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.80 | 0.75 | 0.85 | - | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 422k | -4.04M | -0.0147 | -0.54 | 2.2M |
Date | Subject | Author | Discuss |
---|---|---|---|
07/3/2022 07:04 | News dropped.... predictable | amaretto1 | |
06/3/2022 08:42 | Lots of ramp gang disappeared too | amaretto1 | |
06/3/2022 08:41 | U usually appear ... and news drops ! With your 14 posts on EVG since 2020 ... none of them been favourable. | amaretto1 | |
05/3/2022 22:18 | I agree with Diamondstar1. If Big Pharma were interested in SFX-01, they would have acted years ago. What has the CBO been doing? Meeting with glioblastoma potential partners???? What has the CMO been doing? To my knowledge, there has been no public statement recently about the FDA. Has he created a clinical plan for glioblastoma? Silence from the Chairman? What has he been doing??? Silence from CEO. What has he been doing? The lack of accountability is astounding. There seems to be no effort by the major investors to intervene. Why not?? Perhaps, they are comfortable with the management team and BoD treating the company as their personal retirement account??? | mrwizard1 | |
05/3/2022 11:06 | Were have all the ramp brigade gone ?? | amaretto1 | |
05/3/2022 10:33 | Im hoping kights tax incentives for buying Evgen far outweigh his paper loss, I estimate it's over a million. Imho I would say a good buy /position increase would be around the all time low of 2.80p. I would expect some kind of bounce from there, but in general there is nothing on the immediate horizon to get excited about apart from Kight possibly increasing his position. We should force a resolution through where monthly pay cheques are replaced with shares only, that will either incentivise the board or lead to mass resignation. Probably the latter looking at how little skin they have in the game | kingalf | |
04/3/2022 23:41 | Times like this you wish you were sat in cash but not many ever are , just look at the bargain prices around including this if you have any level of time horizon and patience.This still has life changing potential imo - strong hold for me as no cash | markth126 | |
04/3/2022 18:49 | Tell james kight | amaretto1 | |
04/3/2022 16:05 | Remember that Reata’s Bardoloxone (a NRF-2 activator) also received non-approval by FDA very recently for a renal (kidney) indication. Reata, in my mind, are very much more knowledgeable and experienced in clinical drug development compared to Evgen. What chance has Evgen got in getting SFX-01 approved in oncology- when it has been dabbling in this area (such as breast cancer) for many years? It is a bit like pointing a water pistol at a raging fire… I’m sorry, that’s my opinion on Evgen. Market valuation now equivalent to cash position. If I were an Evgen shareholder, I would cut loss at this level. Why? Because the board of directors are simply sapping the life out of this company, without any significant deliverables. Within 2 years, the £10 million will be gone. Apologies for my negativity- this is my humble opinion (I don’t hold any positions including any short positions on Evgen). | diamondstar1 | |
03/3/2022 17:19 | Just have to bide your time, even I did not expect it to fall to this level but the drums of war have effects and you need to be brave in these situations imo. Hold tight as they work towards building a successful wide range of rewarding products. | clocktower | |
03/3/2022 13:27 | I will add my own dissatisfied voice to the others here. Very unimpressed and trying not to assume the worst, unless proven otherwise soon. No official news to justify this share price collapse, but we have also simply drifted downwards for months now, and this is when the lack of decent inside buying really hurts holders IMO. Capitulation perhaps? Leaky ship? No idea. Not adding but not selling either. Certainly not a happy bunny whatsoever. GLA. | lovewinshatelosses | |
03/3/2022 12:54 | Nobby must be bankrupt | amaretto1 | |
03/3/2022 12:48 | What the xxxx is going on here!!! Killing me here! Another one to be forgotten about.... | markth126 | |
03/3/2022 11:51 | Trading at cash now - he must be very impressed with the share progress since he was appointed. Never gone up and never purchased any stock even at or near all time low, should be taking a pay freeze. | peanut100 | |
03/3/2022 09:19 | A good measure of a CEO's ability might be to give them £10m cash and see how much shareholder value they can create in a year. On that measure Huw you and the rest of your C-suite are utterly diabolical. Well done, you useless wastes of space. | on target | |
21/2/2022 14:24 | Completely agree with you...and that is without even addressing how the CPI data is well short of the real rate of inflation tax that we face right now! How anyone has government bonds right now is beyond me too. Personally, I find it tricky to determine how much cash to keep on the sidelines...too much 'trash cash' is no good, but not enough limits the number of shopping opportunities that present themselves. A better headache to have than the one that accompanies empty pockets - although our politicians are doing their best to clean us out :) | lovewinshatelosses | |
21/2/2022 14:00 | lovewin______ In the main that is what I have done for a while now, but being cash rich is not always the right thing as inflation eats your money - it is nothing but a government tax. Buying slowly on the way down with these cash rich companies that have huge potential seems like a very good risk to reward case imo. | clocktower | |
21/2/2022 13:36 | If I did not already have bundles of these, I would take more sub 5p as well - but I am going to sit on my hands (for once!) | lovewinshatelosses | |
21/2/2022 13:33 | I just had to have a nibble at under 4.5p today and see where we go from here. | clocktower | |
21/2/2022 13:20 | One really good snip of news and we can all pile in here as it is likely to move quickly imo. Still, the market is shaking in nearly all directions today and Putin is one of the major problems, as we all know. Still, security business might be on the up. | clocktower | |
21/2/2022 13:05 | SNG was/is an asthma and COPD play. Covid propelled the share price forward, but the company was around many years before 2019. It was not a covid stock. Anyway, it might still come good, but I think I am going to quit while ahead on that one. Meanwhile, hopefully not too much longer to wait for further news on some of our own developments here. | lovewinshatelosses | |
21/2/2022 12:56 | Well the covid stocks were in general way over valued, so the news impacted like a shell hitting its target. I hope you were not deeply in there markth126. | clocktower | |
21/2/2022 12:24 | Tell me about it! I sold out of my small free carry over at SNG today for about a tenth of what I thought the number would be eventually. Ah well. Most of my small cap holdings elsewhere are getting killed today to add to the irritation. Going to sit on my hands for a while. I do not need to access the money from my p/f (thank heavens!!), or I would have to lock in some pretty serious losses on some of them - this one included. Some over on the SNG LSE board seem to have got in too deep. I hope nobody does anything drastic. The markets can be brutal, but nonetheless, going all in is crazy, especially on a pre-revenue small cap (at least STX has an approved drug, but that is a hairy ride as well). GLA. | lovewinshatelosses | |
21/2/2022 12:05 | i expected more selling today here as people sell to cover stop losses or margin calls over at SNG, disaster of a day there | markth126 |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions